Evolution of antiviral resistance mutations and their biological and biophysical implications
抗病毒耐药突变的演变及其生物学和生物物理意义
基本信息
- 批准号:10363026
- 负责人:
- 金额:$ 64.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-09-01 至 2022-08-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
ABSTRACT
HIV-1 under antiretroviral treatment selects for genetically-linked mutations that are correlated due to
constraints on protein structural stability and function, which contribute to fitness. Project 5 studies are
concerned with analyzing pairs (or higher-order) patterns of antiretroviral resistance mutations and their
combined biophysical, biochemical, and structural effects on drug-resistance and viral fitness. During the past
funding period, new statistical methods were developed to identify correlative mutational patterns present in
genetically unlinked Gag and protease deep sequencing data. Potts Hamiltonian probabilistic models were
constructed from protease sequence alignments to identify mutational patterns that lead to drug-resistance.
To extend the past findings, it is proposed to identify genetically-linked patterns of antiretroviral resistance
mutations from full-length, individual viruses from clade B or non-clade B HIV-infected patients during
antiretroviral treatment. To investigate structural constraints in HIV proteins that influence selection of
resistance mutations, Potts models of protein sequence covariation will be developed utilizing sequence and
structural data. The combination of a novel full-length sequencing approach and virology expertise by Torbett
will be complemented by bioinformatics and modeling expertise of Levy to serve the following specific aims:
1) Identify genetically-linked drug-resistance mutations (pairs or higher order) from HIV in longitudinal patient
samples utilizing Multi-read Barcode-Assisted Single Molecule Sequencing (MrBASMS). Covariant
mutations will be functionally and structurally characterized using previously described biochemical,
biophysical and virological assays to validate their role in the rise of drug resistance.
2) Both full-length, from 1), and HIV sequence data from databases and structural information will be utilized to
construct Potts models of drug naïve and drug-experienced protease, reverse transcriptase, integrase and
Gag. Potts models will be used to investigate the effects of epistatic mutational combinations on fitness, as
well as predict HIV protein residues at risk for drug-resistance mutation development. These studies will
provide critical insight into HIV genetic barriers that must be overcome to develop resistance to multiple
inhibitor combinations.
The MrBASMS sequencing of HIV quasispecies from longitudinal patient samples will be led by Torbett and
Sarafianos, along with outside collaborator Routh (UTMB). The biochemical, structural and virological
validation of mutational covariants will be led by Torbett, Sarafianos and Levy, along with assistance from
Core 2. Levy will develop Potts models from HIV sequence data and protein structural information obtained
from Projects 1, 2, and Core 1.
摘要
接受抗逆转录病毒治疗的HIV-1选择与以下因素相关的遗传连锁突变:
限制蛋白质的结构稳定性和功能,这有助于健身。项目5研究是
涉及分析抗逆转录病毒耐药突变的成对(或更高阶)模式及其
结合生物物理、生物化学和结构对耐药性和病毒适应性的影响。在过去
在资助期间,开发了新的统计方法来确定存在于
遗传上未关联的Gag和蛋白酶深度测序数据。波茨汉密尔顿概率模型是
通过蛋白酶序列比对构建,以鉴定导致耐药性的突变模式。
为了扩展过去的发现,建议确定抗逆转录病毒耐药的遗传连锁模式
来自进化枝B或非进化枝B HIV感染患者的全长单个病毒的突变,
抗逆转录病毒治疗为了研究HIV蛋白质中影响选择的结构限制,
耐药突变,Potts模型的蛋白质序列共变异将开发利用序列和
结构数据Torbett的新型全长测序方法和病毒学专业知识的结合
将由Levy的生物信息学和建模专业知识进行补充,以实现以下具体目标:
1)识别纵向患者中HIV的遗传连锁耐药突变(成对或更高阶)
利用多读段条形码辅助单分子测序(MrBASMS)对样品进行测序。协变
突变将使用先前描述的生物化学,
生物物理学和病毒学分析,以验证它们在耐药性上升中的作用。
2)来自1)的全长和来自数据库的HIV序列数据和结构信息将用于
构建未经药物治疗和药物治疗的蛋白酶、逆转录酶、整合酶和
恶心Potts模型将用于研究上位突变组合对适应性的影响,如
并预测HIV蛋白质残基对耐药性突变发展的风险。这些研究将
提供关键的洞察艾滋病毒的遗传障碍,必须克服发展耐药性的多种
抑制剂组合。
来自纵向患者样本的HIV准种的MrBASMS测序将由Torbett领导,
萨拉菲亚诺斯,沿着与外部合作者劳斯(UTMB)。生物化学,结构和病毒学
突变协变的验证将由Torbett、Sarafianos和Levy领导,沿着由
核心2。Levy将从HIV序列数据和获得的蛋白质结构信息中开发Potts模型
项目1、2和核心1。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ronald Levy其他文献
Ronald Levy的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ronald Levy', 18)}}的其他基金
Mechanisms of HIV fitness and drug resistance inferred from high-resolution molecular dynamics and sequence co-variation models
从高分辨率分子动力学和序列共变模型推断出 HIV 适应性和耐药性的机制
- 批准号:
10750627 - 财政年份:2023
- 资助金额:
$ 64.71万 - 项目类别:
Mapping Fitness and Free Energy Landscapes of Proteins
绘制蛋白质的健康度和自由能景观
- 批准号:
10609895 - 财政年份:2019
- 资助金额:
$ 64.71万 - 项目类别:
Mapping Fitness and Free Energy Landscapes of Proteins
绘制蛋白质的健康度和自由能景观
- 批准号:
9906947 - 财政年份:2019
- 资助金额:
$ 64.71万 - 项目类别:
Mapping Fitness and Free Energy Landscapes of Proteins
绘制蛋白质的健康度和自由能景观
- 批准号:
10577469 - 财政年份:2019
- 资助金额:
$ 64.71万 - 项目类别:
Mapping Fitness and Free Energy Landscapes of Proteins
绘制蛋白质的健康度和自由能景观
- 批准号:
10402303 - 财政年份:2019
- 资助金额:
$ 64.71万 - 项目类别:
Computer Cluster for Computational Biology and Biophysics
计算生物学和生物物理学计算机集群
- 批准号:
8826397 - 财政年份:2015
- 资助金额:
$ 64.71万 - 项目类别:
Evolution of antiviral resistance mutations and their biological and biophysical implications
抗病毒耐药突变的演变及其生物学和生物物理意义
- 批准号:
10242909 - 财政年份:2012
- 资助金额:
$ 64.71万 - 项目类别:
Computer Simulations of Protein Structure and Dynamics
蛋白质结构和动力学的计算机模拟
- 批准号:
7932626 - 财政年份:2009
- 资助金额:
$ 64.71万 - 项目类别:
ATLR 9 AGONIST, COMBINED WITH LOCAL RADIATION IN RECURRENT LOW-GRADE LYMPHOMAS
ATLR 9 激动剂结合局部放射治疗复发性低度淋巴瘤
- 批准号:
7605212 - 财政年份:2007
- 资助金额:
$ 64.71万 - 项目类别:
CLINICAL TRIAL: KLH WITH GM-CSF, IN PATIENTS WITH FOLLICULAR NON-HODGKIN'S LYMPH
临床试验:KLH 联合 GM-CSF,用于滤泡性非霍奇金淋巴瘤患者
- 批准号:
7717852 - 财政年份:2007
- 资助金额:
$ 64.71万 - 项目类别:
相似国自然基金
SENP5调控磷酸化STAT2的SUMO修饰促进抗病毒天然免疫的机制研
究
- 批准号:
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
转录因子IRF3的泛素和SUMO修饰调节机制及其在抗病毒天然免疫中的功能
- 批准号:31130020
- 批准年份:2011
- 资助金额:315.0 万元
- 项目类别:重点项目
相似海外基金
A novel approach to pinpoint predisposed recombination regions in HIV for a global profile of HIV recombinants' occurrence and evolution
一种查明 HIV 中易发生重组区域的新方法,以了解 HIV 重组体发生和进化的全球概况
- 批准号:
10762779 - 财政年份:2023
- 资助金额:
$ 64.71万 - 项目类别:
HIV-1 dynamics and evolution during trispecific broadly neutralizing antibody therapy
三特异性广泛中和抗体治疗期间的 HIV-1 动力学和进化
- 批准号:
10258850 - 财政年份:2021
- 资助金额:
$ 64.71万 - 项目类别:
Consequences of IFIT Gene Evolution on Species-Specific Antiviral Immunity
IFIT 基因进化对物种特异性抗病毒免疫的影响
- 批准号:
8951615 - 财政年份:2016
- 资助金额:
$ 64.71万 - 项目类别:
Consequences of IFIT Gene Evolution on Species-Specific Antiviral Immunity
IFIT 基因进化对物种特异性抗病毒免疫的影响
- 批准号:
9272360 - 财政年份:2016
- 资助金额:
$ 64.71万 - 项目类别:
Viral Evolution and Humoral Immune Response to Dual HIV-1 Infection
双重 HIV-1 感染的病毒进化和体液免疫反应
- 批准号:
8675482 - 财政年份:2013
- 资助金额:
$ 64.71万 - 项目类别:
Evolution of antiviral resistance mutations and their biological and biophysical implications
抗病毒耐药突变的演变及其生物学和生物物理意义
- 批准号:
10242909 - 财政年份:2012
- 资助金额:
$ 64.71万 - 项目类别:
Health Disparities and SARS-COV-2 Evolution: A Focused Viral Genomics Study
健康差异和 SARS-COV-2 进化:一项重点病毒基因组学研究
- 批准号:
10381371 - 财政年份:2012
- 资助金额:
$ 64.71万 - 项目类别:
Constraints on the evolution of influenza oseltamivir resistance
流感奥司他韦耐药性进化的限制
- 批准号:
8324193 - 财政年份:2011
- 资助金额:
$ 64.71万 - 项目类别: